{"id":"preventive-treatment-with-isoniazid","safety":{"commonSideEffects":[{"rate":"1-2","effect":"Peripheral neuropathy"},{"rate":"0.5-3","effect":"Hepatotoxicity"},{"rate":"0.1-0.5","effect":"Hypersensitivity reactions"},{"rate":"0.1-0.2","effect":"Drug-induced lupus"},{"rate":"1-3","effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL64","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isoniazid is a prodrug that is activated by the mycobacterial enzyme catalase-peroxidase (KatG). Once activated, it forms a complex with NAD that inhibits InhA, an enoyl-ACP reductase essential for mycolic acid synthesis in the mycobacterial cell wall. This disruption of cell wall integrity leads to bacterial death or growth inhibition.","oneSentence":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, thereby killing or stopping the growth of Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:35.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Preventive treatment of tuberculosis infection (latent TB infection prophylaxis)"}]},"trialDetails":[{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT07124559","phase":"PHASE1, PHASE2","title":"A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-05-15","conditions":"Tuberculosis","enrollment":144},{"nctId":"NCT06214910","phase":"NA","title":"ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-02-20","conditions":"Tuberculosis, HIV I Infection","enrollment":301},{"nctId":"NCT07086820","phase":"NA","title":"Window Prophylaxis for Pediatric Tuberculosis Prevention Trial","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-10-27","conditions":"Tuberculosis Infection, Household Contacts, Children","enrollment":647},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT05118490","phase":"PHASE4","title":"Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-07-19","conditions":"HIV Seropositivity, Tuberculosis, Household Contact","enrollment":1000},{"nctId":"NCT05122026","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-01-17","conditions":"HIV Seropositivity, Pregnancy, Tuberculosis Infection","enrollment":252},{"nctId":"NCT07058090","phase":"PHASE1","title":"Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi","status":"NOT_YET_RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07","conditions":"Drug Induced Liver Injury, Tuberculosis (TB)","enrollment":410},{"nctId":"NCT03568383","phase":"PHASE3","title":"Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-03","conditions":"Tuberculosis, MDR","enrollment":5832},{"nctId":"NCT03934931","phase":"NA","title":"Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-07-13","conditions":"Tuberculosis, Latent Tuberculosis, HIV/AIDS","enrollment":1656},{"nctId":"NCT06191692","phase":"PHASE3","title":"1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2025-08-01","conditions":"Tuberculosis Infection","enrollment":350},{"nctId":"NCT03785106","phase":"PHASE3","title":"Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals","status":"ACTIVE_NOT_RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-08-15","conditions":"HIV-infected Participants With Latent TB Infection in High TB Burden Country","enrollment":2500},{"nctId":"NCT06874725","phase":"PHASE4","title":"Latent Tuberculosis in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2018-04-18","conditions":"Latent Tuberculosis Infection","enrollment":552},{"nctId":"NCT06281834","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-11-15","conditions":"Pediatric HIV Infection, Latent Tuberculosis","enrollment":25},{"nctId":"NCT06512831","phase":"NA","title":"Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-06-01","conditions":"Kidney Transplantation, Tuberculosis, Isoniazid Toxicity","enrollment":1348},{"nctId":"NCT06484530","phase":"PHASE4","title":"Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-03-12","conditions":"Tuberculosis (TB), Isoniazid Toxicity, Rifampicin Toxicity","enrollment":116},{"nctId":"NCT00351702","phase":"PHASE3","title":"Preventive Therapy for Tuberculosis in HIV Infected Persons","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2001-02","conditions":"Human Immunodeficiency Virus, Tuberculosis","enrollment":683},{"nctId":"NCT04094012","phase":"PHASE3","title":"Risk of SDRs Under 3HP and 1HP Regimen for LTBI","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-09-24","conditions":"Latent Tuberculosis Infection","enrollment":490},{"nctId":"NCT05330884","phase":"PHASE3","title":"BCG Revaccination in Children and Adolescents","status":"SUSPENDED","sponsor":"Tuberculosis Research Centre, India","startDate":"2024-07-15","conditions":"Tuberculosis Infection, Tuberculosis","enrollment":9200},{"nctId":"NCT04600167","phase":"PHASE3","title":"Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus","status":"UNKNOWN","sponsor":"Dr. Nyanda Elias Ntinginya","startDate":"2022-06-17","conditions":"Diabetes Mellitus, Tuberculosis","enrollment":3000},{"nctId":"NCT01934309","phase":"NA","title":"Clinical Decision-support Reminders to Improve IPT Initiation Among HIV Positive Adults in Western Kenya","status":"COMPLETED","sponsor":"Indiana University","startDate":"2013-09","conditions":"Tuberculosis","enrollment":3782},{"nctId":"NCT03435146","phase":"PHASE1, PHASE2","title":"Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)","status":"COMPLETED","sponsor":"The Aurum Institute NPC","startDate":"2018-01-18","conditions":"Respiratory Tract Infections, HIV Infections","enrollment":135},{"nctId":"NCT05085171","phase":"PHASE3","title":"An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease","status":"RECRUITING","sponsor":"Makerere University","startDate":"2022-05-04","conditions":"The Study Will Focus on Assessing the Survival Benefit on an Enhanced Package of Care for Patients With Advanced HIV Disease","enrollment":2400},{"nctId":"NCT05249699","phase":"NA","title":"The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2022-04-01","conditions":"Kidney Transplant Infection, Tuberculosis, Isoniazid Toxicity","enrollment":303},{"nctId":"NCT00000959","phase":"NA","title":"Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":600},{"nctId":"NCT01404312","phase":"PHASE3","title":"Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05-23","conditions":"Tuberculosis, HIV Infections","enrollment":3000},{"nctId":"NCT00000636","phase":"NA","title":"Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":2000},{"nctId":"NCT00000638","phase":"NA","title":"Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":2000},{"nctId":"NCT02383849","phase":"","title":"IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-08-04","conditions":"Low-Birth-Weight Infant, Tuberculosis, HIV","enrollment":124},{"nctId":"NCT01926379","phase":"NA","title":"ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-07","conditions":"HIV, Tuberculosis","enrollment":338},{"nctId":"NCT03723525","phase":"PHASE4","title":"Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals","status":"COMPLETED","sponsor":"National Centre for AIDs and STD Control, Nepal","startDate":"2018-01-22","conditions":"HIV","enrollment":1073},{"nctId":"NCT04528277","phase":"PHASE3","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2020-09-01","conditions":"Infertility, Female, Recurrent Implantation Failure, Genital Tuberculoses, Female","enrollment":1050},{"nctId":"NCT02430259","phase":"PHASE3","title":"Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-03","conditions":"Silicosis, Tuberculosis","enrollment":566},{"nctId":"NCT03074799","phase":"NA","title":"Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-10-01","conditions":"Tuberculosis","enrollment":4054},{"nctId":"NCT00816426","phase":"PHASE1","title":"Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-12-29","conditions":"Tuberculosis","enrollment":19},{"nctId":"NCT03028129","phase":"PHASE4","title":"Prevention of Tuberculosis in Prisons","status":"TERMINATED","sponsor":"Federal University of Mato Grosso","startDate":"2017-09-04","conditions":"Tuberculosis, Pulmonary, Antibiotic Prophylaxis","enrollment":467},{"nctId":"NCT00330304","phase":"PHASE3","title":"Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2003-01","conditions":"Tuberculosis","enrollment":450},{"nctId":"NCT03900858","phase":"NA","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-12-01","conditions":"Silicosis Tuberculosis","enrollment":566},{"nctId":"NCT00080119","phase":"PHASE2, PHASE3","title":"Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2004-02","conditions":"HIV Infection, Tuberculosis, Pneumocystis Jiroveci Pneumonia","enrollment":1354},{"nctId":"NCT00170209","phase":"PHASE3","title":"Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)","status":"COMPLETED","sponsor":"McGill University","startDate":"2011-08","conditions":"Latent Tuberculosis Infection","enrollment":844},{"nctId":"NCT02208427","phase":"PHASE3","title":"Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-08","conditions":"Latent Tuberculosis Infection","enrollment":283},{"nctId":"NCT01223534","phase":"PHASE4","title":"QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2010-07","conditions":"Latent Tuberculosis Infection","enrollment":871},{"nctId":"NCT01825031","phase":"PHASE3","title":"Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy","status":"COMPLETED","sponsor":"Anna Griffiths, MRC","startDate":"2013-06","conditions":"Human Immunodeficiency Virus","enrollment":1805},{"nctId":"NCT00164281","phase":"PHASE4","title":"Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-11","conditions":"Tuberculosis, HIV Infections","enrollment":2000},{"nctId":"NCT00850915","phase":"PHASE4","title":"Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya","status":"COMPLETED","sponsor":"KNCV Tuberculosis Foundation","startDate":"2009-04","conditions":"Tuberculosis","enrollment":1259},{"nctId":"NCT00463086","phase":"NA","title":"Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2007-11","conditions":"Tuberculosis, Latent Tuberculosis Infection, HIV Infections","enrollment":1368},{"nctId":"NCT01398618","phase":"PHASE3","title":"Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2011-05","conditions":"Latent Tuberculosis Infection","enrollment":300},{"nctId":"NCT00107887","phase":"PHASE4","title":"TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2005-06","conditions":"Tuberculosis, HIV Infections","enrollment":17415}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3229,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Preventive treatment with Isoniazid","genericName":"Preventive treatment with Isoniazid","companyName":"Hospital Universitari de Bellvitge","companyId":"hospital-universitari-de-bellvitge","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, thereby killing or stopping the growth of Mycobacterium tuberculosis. Used for Preventive treatment of tuberculosis infection (latent TB infection prophylaxis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}